OBSERVATIONAL STUDY OF RESPONSE AND TOXICITY OF CONCURRENT CHEMO RADIOTHERAPY FOLLOWED BY CONSOLIDATION CHEMOTHERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG CARCINOMA

Dr Y. Vishnu Vardhan Reddy, Dr M. Radhika Rani, Dr Syed Mustafa Hashmi, Suhas Mareedu

Abstract


For  Non-Small  Cell  Lung  Cancer  (NSCLC)  simultaneous  administration  of radiotherapy  with  chemotherapy  (concurrent  or  concomitant  chemoradiation)  followed  by  further  chemotherapy  (consolidation  chemotherapy)  has  been  shown  to  have  better  results  compared  to  chemotherapy  or  radiotherapy  alone.  This  study  analysed  the  efficacy  and  effects  of  the  same  in  Stage  III  NSCLC  cases. 30  patients  with  proven  stage  III  NSCLC  who  met  the  inclusion  criteria  were  treated  with  6  MV  LINAC  with  MLC  (3DCRT  Planning).  At  the  completion  of  concurrent  treatment,  15%  were  CR  and  59%  were  PR.  At  3  months  of  follow-up,  a  total  of  nearly  70%  patients  responded  to  the  treatment.  The  adverse  effects  studied  included  Esophagitis,  Pneumonitis,  Neutropenia,  Thrombocytopenia  and  Leukopenia  for  a  3  month  follow  up  period.  The  results  obtained  in  our  study  support  the  observation  that  concurrent/consolidation  chemoradiation  with  platinum  containing  regimens  are  superior  to  radiotherapy  alone  in  terms  of  overall  survival,  disease-free  survival  and  local  control.


Keywords


Concurrent chemoradiation, Radiotherapy, Consolidation chemotherapy, Non-Small Cell Lung Cancer

Full Text:

PDF

References


Ferlay J et al GLOBOCAN 2008, Cancer Incidence & Mortality Worldwide: IARC Cancerbase 2010.

GLOBOCAN 2012, IARC.

3) Behera, D; Balamugesh T "Lung cancer in India" IJCDAS (2004); 46 (4): 269–81.

Ganesh B et al: Case-control Study of Risk Factors for Lung Cancer in Mumbai. Asian Pac J Cancer 2011;12:357-62.

Nobuyuki Yamamoto et al. Phase III Study Comparing Second and Third Generation Regimens with Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III NSCLC; J Clin Oncol 2010; 28(23):3739-45.

Belani CP et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced NSCLC. J Clin Oncol. 2005;23:5883–91.

NSCLC Collaborative Group Chemotherapy: a meta-analysis using data on individual patients from 52 RCTs. BMJ. 1995; 311:899–909.

Le Chevalier T et al. Radiotherapy alone versus combined chemoradiotherapy in nonresectable NSCLC. J Natl Cancer Inst. 1991;83: 41


Refbacks

  • There are currently no refbacks.